Author:
Janoray G.,Bruguière E.,Mazurier J.,Dudouet P.,Guillotreau J.,Tollon C.,Labarthe P.,Seguin P.,Latorzeff I.
Publisher
Springer Science and Business Media LLC
Reference42 articles.
1. de Crevoisier R, Supiot S, Créhange G, Pommier P, Latorzeff I, Chapet O, et al. External radiotherapy for prostatic cancers. Cancer Radiothér. 2022;26(1–2):329–43.
2. Urofrance | Recommandations françaises du Comité de cancérologie de l’AFU – actualisation 2020–2022 : cancer de la prostate – Urofrance. Disponible sur: https://www.urofrance.org/recommandation/recommandations-francaises-du-comite-de-cancerologie-de-lafu-actualisation-2020-2022-cancer-de-la-prostate/. Cité 18 mai 2022
3. D’Amico A, Altschuler M, Whittington R, Kao G, Malkowicz SB, Wein A. The use of clinical parameters in an interactive statistical package to predict pathological features associated with local failure after radical prostatectomy for prostate cancer. Clin Perform Qual Health Care. 1993;1(4):219–22.
4. Hamdy FC, Donovan JL, Lane JA, Metcalfe C, Davis M, Turner EL, et al. Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med. 2023;388(17):1547–58.
5. Pollack A, Zagars GK, Starkschall G, Antolak JA, Lee JJ, Huang E, et al. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys. 2002;53(5):1097–105.